Seek Returns

BBIO vs. PCVX: BridgeBio Pharma vs. Vaxcyte Stock Comparison

How do BridgeBio Pharma (BBIO) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BridgeBio Pharma (BBIO) and Vaxcyte (PCVX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)
Profile ItemBBIOPCVX
NameBridgeBio Pharma Inc.Vaxcyte Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization14.47 billion USD10.11 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 27, 2019June 12, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BBIO
PCVX
GSPC
Loading price history…
BridgeBio Pharma (BBIO) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for BridgeBio Pharma (BBIO) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for BridgeBio Pharma (BBIO) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)
MetricBBIOPCVX
Total Return (1Y)22.70%59.00%
Total Return (3Y, Annualized)40.97%11.29%
Total Return (5Y, Annualized)8.25%21.60%

Risk Profile

Drawdown History

BBIO
PCVX
GSPC
Loading price history…
BridgeBio Pharma (BBIO) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for BridgeBio Pharma (BBIO) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)
MetricBBIOPCVX
Volatility (1Y, Annualized)44.39%56.01%
Beta (5Y)0.931.26
Max Drawdown (5Y)-89.79%-76.22%
Avg. Volume (3M)2.68M2.12M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BBIO and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)
MetricBBIOPCVX
Sharpe Ratio (1Y)0.410.98
Sortino Ratio (1Y)0.631.76

Profitability

ROE (TTM)

BridgeBio Pharma (BBIO) has no ROE value reported for this period; Vaxcyte (PCVX) reports a negative figure of -42.68%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
BBIO
--

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%
Loading chart…
BridgeBio Pharma (BBIO) vs. Vaxcyte (PCVX): BBIO does not report ROE, so it has no value marker; PCVX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile Vaxcyte (PCVX) reports 0.00%, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-59.84%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
BBIO
-59.84%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
BridgeBio Pharma (BBIO) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Vaxcyte (PCVX) reports 0.00%, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-3.30%

Max
83.12%
Q3
14.77%
Median
0.00%
BBIO
-3.30%
Q1
-78.82%
Min
-207.40%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
BridgeBio Pharma (BBIO) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)
MetricBBIOPCVX
ROE (TTM)---42.68%
ROA (TTM)-13.97%-24.98%
Net Margin (TTM)-59.84%0.00%
Operating Margin (TTM)-3.30%0.00%
Gross Margin (TTM)94.34%0.00%

Growth

Revenue Growth

Only one side can be read here: BridgeBio Pharma (BBIO) reports revenue growth of 126.26%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
BridgeBio Pharma (BBIO) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither BridgeBio Pharma (BBIO) nor Vaxcyte (PCVX) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)
MetricBBIOPCVX
Revenue Growth (YoY)126.26%--
Revenue Growth (3Y CAGR)86.30%--
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while BridgeBio Pharma (BBIO) at 2.09 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BBIO.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.09

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BBIO
2.09
Min
0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10
Loading chart…
BridgeBio Pharma (BBIO) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Vaxcyte (PCVX) carries debt-to-equity ratio of 0.09 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
BBIO
--

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00
Loading chart…
BridgeBio Pharma (BBIO) vs. Vaxcyte (PCVX): BBIO does not report debt-to-equity ratio, so it has no value marker; PCVX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)
MetricBBIOPCVX
Current Ratio (MRQ)2.094.56
Debt / Equity (MRQ)--0.09
Net Debt / EBITDA----

Dividends

Dividend Yield (TTM)

Neither BridgeBio Pharma (BBIO) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BridgeBio Pharma (BBIO) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither BridgeBio Pharma (BBIO) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BridgeBio Pharma (BBIO) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)
MetricBBIOPCVX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Neither BridgeBio Pharma (BBIO) nor Vaxcyte (PCVX) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
BBIO
--

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--
Loading chart…
BridgeBio Pharma (BBIO) vs. Vaxcyte (PCVX): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

A sales-based read is only available for BridgeBio Pharma (BBIO), whose P/S ratio of 15.31 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.31

Max
58.18
Q3
25.77
BBIO
15.31
Median
7.30
Q1
3.01
Min
0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--
Loading chart…
BridgeBio Pharma (BBIO) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; BBIO is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Vaxcyte (PCVX) reports 3.83, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-5.59

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BBIO
-5.59
Min
-5.59

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
BridgeBio Pharma (BBIO) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)
MetricBBIOPCVX
P/E Ratio (TTM)----
P/S Ratio (TTM)15.31--
P/B Ratio (MRQ)-5.593.83
Free Cash Flow Yield (TTM)-1.98%-5.24%